Immune therapy in type 1 diabetes mellitus

@article{Lernmark2013ImmuneTI,
  title={Immune therapy in type 1 diabetes mellitus},
  author={{\AA}. Lernmark and H. Larsson},
  journal={Nature Reviews Endocrinology},
  year={2013},
  volume={9},
  pages={92-103}
}
Type 1 diabetes mellitus (T1DM) is an autoimmune disorder directed against the β cells of the pancreatic islets. The genetic risk of the disease is linked to HLA-DQ risk alleles and unknown environmental triggers. In most countries, only 10–15% of children or young adults newly diagnosed with T1DM have a first-degree relative with the disease. Autoantibodies against insulin, GAD65, IA-2 or the ZnT8 transporter mark islet autoimmunity. These islet autoantibodies may already have developed in… Expand
Advances in immunotherapy of type I diabetes.
TLDR
This review attempts to capture the current state of T1DM immunotherapy by highlighting representative studies and suggesting drug delivery field has much to offer in maximizing the benefits of immune modulators by optimizing spatiotemporal presentation of antigens and costimulatory signals. Expand
Diabetes as autoimmune disease-Diabetes type
Type 1 diabetes mellitus (T1D), also known as insulin dependent diabetes mellitus, is a chronic immune mediated disease that is characterized by selective loss of insulin producing β cells of theExpand
Depleting T Cells in Newly Diagnosed Autoimmune (Type 1) Diabetes—Are We Getting Anywhere?
TLDR
The prevalence and incidence of type 1 diabetes are diverse, explained in part by the heterogeneous distribution of HLA genetic factors on chromosome 6 that control the body’s way of dealing with infectious diseases. Expand
Risk Factors and Primary Prevention Trials for Type 1 Diabetes
TLDR
The purpose of this review is to provide an overview of this disorder's pathogenesis, risk factors that cause the disease, as well as to bring forward an ideal approach to prevent and cure the disorder. Expand
Risk Factors and Primary Prevention Trials for Type 1
TLDR
The purpose of this review is to provide an overview of this disorder’s pathogenesis, risk factors that cause the disease, as well as to bring forward an ideal approach to prevent and cure the disorder. Expand
Overcoming barriers in clinical islet transplantation: current limitations and future prospects.
TLDR
Development of the “artificial pancreas,” an integrated closed-loop control system that combines continuous glucose monitoring with subcutaneous insulin infusion, has been shown to significantly improve glycemic control, although refinement for routine ambulatory use is still in evolution. Expand
Immunomodulators in Prophylaxis and Therapy of Type-1 Diabetes
TLDR
This chapter focuses mainly on phytochemical molecules from various plants, which are used for treatment and prophylaxis of T1D, and many of these molecules act as immunomodulators either by avoiding β-cell destruction or by promoting their growth and development. Expand
Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes
TLDR
It is shown that proinsulin peptides are targeted by islet-infiltrating T cells from patients with type 1 diabetes with a short disease duration with high-risk HLA genes using a direct T-cell receptor (TCR) sequencing approach without long-term cell culture. Expand
Islet inflammation in human type 1 diabetes mellitus
TLDR
The evidence which underpins the current understanding of the aetiology of T1DM is reviewed and established features as well as areas of on‐going ambiguity and debate are highlighted. Expand
DiaPep277® and immune intervention for treatment of type 1 diabetes.
TLDR
This review summarizes immune intervention trials and the current knowledge of DiaPep277® peptide as a form of immune intervention in type 1 diabetes and shows partial success in preserving C-peptide in newly diagnosed patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 102 REFERENCES
Autoantibodies in diabetes.
TLDR
Autoantibodies may also provide prognostic information in clinically heterogeneous patient populations when examined longitudinally and may prove useful in identifying triggers of islet autoimmunity by examining seroconversion and maturation of the autoantibody response that may mark time to onset of type 1 diabetes. Expand
Modulating the natural history of type 1 diabetes in children at high genetic risk by mucosal insulin immunization
TLDR
The proposed Pre-POINT (Primary Oral/intranasal INsulin Trial) aims to identify an optimal insulin dose and route of application that is well tolerated and can induce an immune response to insulin for additional use in a phase II/III primary prevention trial in children at risk. Expand
Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1
TLDR
The data indicate that the number of autoantibodies is predictive of type 1 diabetes, however, mIAA is less predictive ofType 1 diabetes than other autoantibia, and must be carefully considered in planning prevention trials fortype 1 diabetes. Expand
Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes
TLDR
The current knowledge of the immunopathogenesis of type 1 diabetes and how this information has been translated into clinical trials is discussed and next-generation combination immunotherapies that may be administered as adjuvant therapy at time of diagnosis are discussed. Expand
Primary Dietary Intervention Study to Reduce the Risk of Islet Autoimmunity in Children at Increased Risk for Type 1 Diabetes
TLDR
Delaying gluten exposure until the age of 12 months is safe but does not substantially reduce the risk for islet autoimmunity in genetically at-risk children. Expand
T Cell Recognition of Autoantigens in Human Type 1 Diabetes: Clinical Perspectives
TLDR
Developing T-cell assays in diabetes autoimmunity is expected to help defining autoantigens and epitopes that drive the disease process, to pinpoint key functional features of epitope-specific T lymphocytes along the natural history of diabetes and to pave the way towards therapeutic strategies to induce immune tolerance to β-cells. Expand
Neonatal Bacille Calmette-Guerin vaccination and type 1 diabetes.
TLDR
There is substantial interest in whether immunostimulation with BCG could be used as a primary, secondary, or tertiary vaccination strategy for type 1 diabetes. Expand
Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial
TLDR
In children with HLA-conferred susceptibility to diabetes, administration of nasal insulin, started soon after detection of autoantibodies, could not be shown to prevent or delay type 1 diabetes. Expand
Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY).
TLDR
It is revealed that cross-sectional determination of islet autoantibodies in a population with relatively low previous probability of autoimmunity identifies as "positive" a large number of individuals who are either false or transiently positive. Expand
Pancreatic β-Cell Function and Immune Responses to Insulin After Administration of Intranasal Insulin to Humans At Risk for Type 1 Diabetes
TLDR
Results from this pilot study suggest that intranasal insulin does not accelerate loss of β-cell function in individuals at risk for type 1 diabetes and induces immune changes consistent with mucosal tolerance to insulin. Expand
...
1
2
3
4
5
...